Bioventix PLC (LON:BVXP – Get Free Report) insider Bruce Hiscock bought 61 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were bought at an average price of GBX 273 ($3.42) per share, with a total value of £166.53 ($208.76).
Bruce Hiscock also recently made the following trade(s):
- On Friday, November 22nd, Bruce Hiscock purchased 24 shares of Bioventix stock. The stock was purchased at an average price of GBX 3,822 ($47.91) per share, for a total transaction of £917.28 ($1,149.91).
- On Wednesday, October 30th, Bruce Hiscock acquired 300 shares of Bioventix stock. The shares were purchased at an average price of GBX 3,330 ($41.75) per share, with a total value of £9,990 ($12,523.51).
Bioventix Stock Performance
Shares of LON:BVXP opened at GBX 3,174.76 ($39.80) on Wednesday. The stock’s 50-day simple moving average is GBX 3,634.44 and its two-hundred day simple moving average is GBX 3,989.98. The stock has a market capitalization of £165.72 million, a price-to-earnings ratio of 1,947.70 and a beta of 0.35. Bioventix PLC has a 52-week low of GBX 2,977 ($37.32) and a 52-week high of GBX 5,100 ($63.93).
Bioventix Increases Dividend
Bioventix Company Profile
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
Further Reading
- Five stocks we like better than Bioventix
- Investing in Construction Stocks
- 5 Reasons DraftKings Stock Looks Promising in the New Year
- What does consumer price index measure?
- Cybersecurity Stocks: 1 Immediate Buy and 1 Dip Opportunity
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- The Next 2 AI Winners Have Triple-Digit Upside Potential
Receive News & Ratings for Bioventix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix and related companies with MarketBeat.com's FREE daily email newsletter.